SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma’s arm, Blue-Zone collaborate to recycle waste anaesthetic gases

06 Feb 2026 Evaluate

Piramal Pharma’s overseas subsidiary -- Piramal Critical Care, Inc. (PCC) and Blue-Zone Technologies (Blue-Zone) have entered into an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers’ efforts to minimize the environmental impact of volatile anaesthetics. This collaboration will also help ensure that these essential products remain the primary method of providing general anaesthesia for patients around the world.

Pending regulatory approval in Europe of Blue-Zone’s Phoenix Deltasorb waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC’s customers in Europe, initially in France and Germany. Blue-Zone will be responsible for all activities involving the supply and use of its systems in healthcare facilities. PCC will process captured waste anaesthetic gas using BlueZone’s technology to produce Sevoflurane USP for human use in Canada. The parties anticipate that the scope of the waste anaesthetic gas capture, collection and recycling, and the marketing of Sevoflurane USP using waste anaesthetic gas, will expand into additional geographies.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

147.45 -1.10 (-0.74%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×